LitAlert ~~ GeneLit.com

    • How should we address the inevitable harms from non-negligent variant reclassification in predictive genetic testing?
    • Rashkin M, Kingham K, Lara-Otero , Mckenna M, Villiers J, Worthington MM, Prince A.
    • J Genet Couns. 2022 Oct 19. doi: 10.1002/jgc4.1638. Epub ahead of print.
    • IN VIVO ASSIGNMENT OF METHYLMALONIC ACID IN BREAST TISSUE USING 2D MAGNETIC RESONANCE SPECTROSCOPY AND RELATIONSHIP WITH BREAST DENSITY, MENOPAUSAL STATUS AND CANCER RISK.
    • Santamaría G, Naude N, Bennett I, Vosburgh K, Ganau S, Bargalló X, Malycha P, Mountford C.
    • NMR Biomed. 2022 Oct 19:e4851. doi: 10.1002/nbm.4851. Epub ahead of print.
    • Genomic characterization of metastatic castration-resistant prostate cancer patients undergoing PSMA radioligand therapy: A single-center experience.
    • Satapathy S, Das CK, Aggarwal P, Sood A, Parihar AS, Singh SK, Mittal BR.
    • Prostate. 2022 Oct 19. doi: 10.1002/pros.24450. Epub ahead of print.
    • RAD6 inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by aggravating mitotic spindle damage.
    • Haynes BM, Cunningham K, Shekhar MPV.
    • BMC Cancer. 2022 Oct 18;22(1):1073. doi: 10.1186/s12885-022-10119-z.
    • Germline Genetic Testing in Breast Cancer: Systemic Therapy Implications.
    • Bhardwaj PV, Abdou YG.
    • Curr Oncol Rep. 2022 Oct 18. doi: 10.1007/s11912-022-01340-x. Epub ahead of print.
    • Review
    • Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984.
    • Kim JW, McKay RR, Radke MR, Zhao S, Taplin ME, Davis NB, Monk P, Appleman LJ, Lara PN Jr, Vaishampayan UN, Zhang J, Paul AK, Bubley G, Van Allen EM, Unlu S, Huang Y, Loda M, Shapiro GI, Glazer PM, LoRusso PM, Ivy SP, Shyr Y, Swisher EM, Petrylak DP.
    • J Clin Oncol. 2022 Oct 18:JCO2102947. doi: 10.1200/JCO.21.02947. Epub ahead of print.

    Identifier: NCT02893917: Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer. (ClinicalTrials.gov . Accessed 2022 Oct 19.)

    • Dr. Karlan on Current Research Evaluating PARP Inhibitor Combination Therapy in Ovarian Cancer.
    • Karlan BY.
    • OncLive. OncLive TV. 2022 Oct 18.